Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

Next Previous
X
Search
Trial Profile

A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Acronyms LuDO-N

    • Most Recent Events

    • 16 Sep 2023 Planned number of patients changed from 24 to 25.
    • 31 May 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT04903899).
    • 25 May 2021 Planned End Date changed from 3 Feb 2031 to 20 May 2031.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top